Added to YB: 2026-02-19
Pitch date: 2026-02-15
NVO [neutral]
Novo Nordisk A/S
-21.54%
current return
Author Info
Octopus Value is a private investor focusing on quality companies with margin of safety Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.1T
Pitch Price
DKK 301.92
Price Target
N/A
Dividend
4.94%
EV/EBITDA
7.46
P/E
10.29
EV/Sales
3.74
Sector
Pharmaceuticals
Category
turnaround
Novo Nordisk - FY 2025 Earnings Review
NVO (earnings): Q4 beat lowered guidance but FY26 outlook -5% to -13% adj sales sent stock ↓14%. US pricing pressure key drag. Wegovy growing all regions, Ozempic flat ex-EUCAN. Restructuring costs DKK 9B masked 44% norm op margin. CapEx peaks DKK 60B FY25, guides DKK 55B FY26 w/ FCF DKK 35-45B. Cagrisema US approval & ziltivekimab Ph3 data key 2026 catalysts.
Read full article (8 min)